Sphk1 and N-AS as drivers of COX2 acetylation have been well explored in AD pathology, as discussed in the above findings, but they remain to be investigated in other neurodegenerative disorders such as PD, HD, and ALS. This evidence concerns the gene SPHK1 and Huntington disease.